Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage therapeutics developer, announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event on December 15, 2020, at 10:40 a.m. EST.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage therapeutics developer, announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event on December 15, 2020, at 10:40 a.m. EST. The event will be available via live webcast.
The company focuses on unmet medical needs in neurotology, rhinology, and CNS disorders, with products like AM-125 for vertigo and AM-111 for acute inner ear hearing loss under development. Auris Medical, founded in 2003, is headquartered in Hamilton, Bermuda, with operations in Basel, Switzerland.
Details
News Market Reaction – EARS
The recorded move for EARS in the trading session of this news was +10.51%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.
About Auris Medical
Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”
Investor contact:
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.